{"id":904745,"date":"2025-11-03T19:10:36","date_gmt":"2025-11-04T00:10:36","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/olema-oncology-to-participate-in-upcoming-investor-conferences-4\/"},"modified":"2025-11-03T19:10:36","modified_gmt":"2025-11-04T00:10:36","slug":"olema-oncology-to-participate-in-upcoming-investor-conferences-4","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/olema-oncology-to-participate-in-upcoming-investor-conferences-4\/","title":{"rendered":"Olema Oncology to Participate in Upcoming Investor Conferences"},"content":{"rendered":"<div class=\"mw_release\">\n<p>SAN FRANCISCO, Nov.  03, 2025  (GLOBE NEWSWIRE) &#8212; <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=ctPskIVoPhk2FKr_HtK3eicTPSPsqgePD52T3_bJW1tWhXX1-lSasmNuraajkvwljhTiwAQdO_bDjS1z3KwGIzrVe0P5el49utKIo3toyzD2lDS9ck9nrGunk4G99_lZTy3jqdVswf9rm0m5SPfqlxuVH9YJDF_cvyvGQdxKr8LDVXQWGrfjmDHwyuXvO0Gj4Ik6ybcTa2O5-0SE8iN7lM73p0SUl-uRxzPVK84ENMLOYc4ocyeuwLd44qyasMTw4QW0JdlgBCFI93HYv2EAQw==\" rel=\"nofollow\" target=\"_blank\">Olema Pharmaceuticals, Inc.<\/a>\u00a0(\u201cOlema\u201d, or \u201cOlema Oncology\u201d, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced that the Company will participate in the following upcoming investor conferences:<\/p>\n<p>\n        <strong>Guggenheim 2<\/strong><br \/>\n        <sup><br \/>\n          <strong>nd<\/strong><br \/>\n        <\/sup><br \/>\n        <strong> Annual Healthcare Innovation Conference <\/strong><br \/>\n        <br \/>Date and Time: November 10, 2025 at 10:30 a.m. ET <br \/>Format: Fireside Chat<br \/>Location: Boston, MA<\/p>\n<p>\n        <strong>UBS Global Healthcare Conference 2025<\/strong><br \/>\n        <br \/>Date and Time: November 12, 2025 at 8:00 a.m. ET<br \/>Format: Presentation<br \/>Location: Palm Beach, FL<\/p>\n<p>\n        <strong>2025 Jefferies London Healthcare Conference <\/strong><br \/>\n        <br \/>Date and Time: November 19, 2025 at 9:00 a.m. GMT \/ 4:00 a.m. ET<br \/>Format: Fireside Chat<br \/>Location: London<\/p>\n<p>Live webcasts and recordings of these presentations will be available, as permitted by the event host, in the Events and Presentations section of Olema\u2019s investor relations website at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=M33JRbqv2ulWUcfSh4w5baDirnr9yAdO9CFyARRYwhLAPJqf7tn4xPWaJTHr1JzYdu8TnOqs-zfKjrSesIlgKuU5ETGP2Rq4KKDY96JwyTCTuwa8kdEbZH-Myvv4RiHwFWy8Xu0jgBvsyuw1jV3TtQNAEA8LAKMrKlLGT3miTELVdDIzWH6fJgG4wvRNsGJqC3IkYKwLCRlRk5ARg_Cbya7yhqf3nTr35hl_6VSkN_I=\" rel=\"nofollow\" target=\"_blank\"><u>ir.olema.com<\/u><\/a>.<\/p>\n<p>\n        <strong>About Olema Oncology<\/strong><br \/>\n        <br \/>Olema Oncology is a clinical-stage biopharmaceutical company committed to transforming the standard of care and improving outcomes for patients living with breast cancer and beyond. Olema is advancing a pipeline of novel therapies by leveraging our deep understanding of endocrine-driven cancers, nuclear receptors, and mechanisms of acquired resistance. Our lead product candidate, palazestrant (OP-1250), is a proprietary, orally available complete estrogen receptor antagonist (CERAN) and a selective estrogen receptor degrader (SERD), currently in two Phase 3 clinical trials. In addition, Olema is developing OP-3136, a potent lysine acetyltransferase 6 (KAT6) inhibitor, now in a Phase 1 clinical study. Olema is headquartered in San Francisco and has operations in Cambridge, Massachusetts. For more information, please visit\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=De5jv7F94ARzWYlDIwIA0lpwppsFF4z5Dwu5Outh6BL2ibBjuOuQcLtxI7t9nDpwAbYBJcHBwm8uzu3ftfaGx4eHBU5hoVaN58ENS8SlCKM6_AybEb0hQDATiqDl139y5B79ZWsu1L0XzfD5OcrvN4w7PAzCS_Op5HAfIwNqQLgp28YN3UBZg0yNgaRqpgN6BZflQDJccAH9BAdDIaZgujQvSAh8oZRvKSXb8HA5kmc=\" rel=\"nofollow\" target=\"_blank\">www.olema.com<\/a>.<\/p>\n<p>\n        <strong>Media and Investor Relations Contact<\/strong><br \/>\n        <br \/>Courtney O\u2019Konek<br \/>Vice President, Corporate Communications<br \/>Olema Oncology<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=C3ZMGjczIKpDiSHeG5H31NF4UBTgSA82x07BiICXOkX5VSJNFGu67ss4YXN-lEgHe_89HXD9RPlOrqaAN_6AukDlSdsmQVCwCrtbE_x0eaWJYjpSsBMDWt-POYmkPzCpTlR7C8Weomt4kGbemrVU0EjoBDEQz7f_RWOv6M4KuS7GgFZ9wzqMMfVxHiJQsWirRDKHe4V6qAnRfI99es6qTDj0Q15tGbwaSodFNixi7_I=\" rel=\"nofollow\" target=\"_blank\">media@olema.com<\/a><\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU2NzYzMCM3MjQwODM2IzIyMDM1MTU=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/NjA5NzJjNGQtZDQ0OC00Nzg3LTgxYzktNzI3Y2RjNmMyYjI1LTEyMTUwNjgtMjAyNS0xMS0wMy1lbg==\/tiny\/Olema-Pharmaceuticals-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>SAN FRANCISCO, Nov. 03, 2025 (GLOBE NEWSWIRE) &#8212; Olema Pharmaceuticals, Inc.\u00a0(\u201cOlema\u201d, or \u201cOlema Oncology\u201d, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced that the Company will participate in the following upcoming investor conferences: Guggenheim 2 nd Annual Healthcare Innovation Conference Date and Time: November 10, 2025 at 10:30 a.m. ET Format: Fireside ChatLocation: Boston, MA UBS Global Healthcare Conference 2025 Date and Time: November 12, 2025 at 8:00 a.m. ETFormat: PresentationLocation: Palm Beach, FL 2025 Jefferies London Healthcare Conference Date and Time: November 19, 2025 at 9:00 a.m. GMT \/ 4:00 a.m. ETFormat: Fireside ChatLocation: London Live webcasts and recordings of these presentations will be &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/olema-oncology-to-participate-in-upcoming-investor-conferences-4\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Olema Oncology to Participate in Upcoming Investor Conferences&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-904745","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Olema Oncology to Participate in Upcoming Investor Conferences - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/olema-oncology-to-participate-in-upcoming-investor-conferences-4\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Olema Oncology to Participate in Upcoming Investor Conferences - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"SAN FRANCISCO, Nov. 03, 2025 (GLOBE NEWSWIRE) &#8212; Olema Pharmaceuticals, Inc.\u00a0(\u201cOlema\u201d, or \u201cOlema Oncology\u201d, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced that the Company will participate in the following upcoming investor conferences: Guggenheim 2 nd Annual Healthcare Innovation Conference Date and Time: November 10, 2025 at 10:30 a.m. ET Format: Fireside ChatLocation: Boston, MA UBS Global Healthcare Conference 2025 Date and Time: November 12, 2025 at 8:00 a.m. ETFormat: PresentationLocation: Palm Beach, FL 2025 Jefferies London Healthcare Conference Date and Time: November 19, 2025 at 9:00 a.m. GMT \/ 4:00 a.m. ETFormat: Fireside ChatLocation: London Live webcasts and recordings of these presentations will be &hellip; Continue reading &quot;Olema Oncology to Participate in Upcoming Investor Conferences&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/olema-oncology-to-participate-in-upcoming-investor-conferences-4\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-11-04T00:10:36+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU2NzYzMCM3MjQwODM2IzIyMDM1MTU=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/olema-oncology-to-participate-in-upcoming-investor-conferences-4\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/olema-oncology-to-participate-in-upcoming-investor-conferences-4\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Olema Oncology to Participate in Upcoming Investor Conferences\",\"datePublished\":\"2025-11-04T00:10:36+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/olema-oncology-to-participate-in-upcoming-investor-conferences-4\\\/\"},\"wordCount\":273,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/olema-oncology-to-participate-in-upcoming-investor-conferences-4\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTU2NzYzMCM3MjQwODM2IzIyMDM1MTU=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/olema-oncology-to-participate-in-upcoming-investor-conferences-4\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/olema-oncology-to-participate-in-upcoming-investor-conferences-4\\\/\",\"name\":\"Olema Oncology to Participate in Upcoming Investor Conferences - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/olema-oncology-to-participate-in-upcoming-investor-conferences-4\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/olema-oncology-to-participate-in-upcoming-investor-conferences-4\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTU2NzYzMCM3MjQwODM2IzIyMDM1MTU=\",\"datePublished\":\"2025-11-04T00:10:36+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/olema-oncology-to-participate-in-upcoming-investor-conferences-4\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/olema-oncology-to-participate-in-upcoming-investor-conferences-4\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/olema-oncology-to-participate-in-upcoming-investor-conferences-4\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTU2NzYzMCM3MjQwODM2IzIyMDM1MTU=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTU2NzYzMCM3MjQwODM2IzIyMDM1MTU=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/olema-oncology-to-participate-in-upcoming-investor-conferences-4\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Olema Oncology to Participate in Upcoming Investor Conferences\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Olema Oncology to Participate in Upcoming Investor Conferences - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/olema-oncology-to-participate-in-upcoming-investor-conferences-4\/","og_locale":"en_US","og_type":"article","og_title":"Olema Oncology to Participate in Upcoming Investor Conferences - Market Newsdesk","og_description":"SAN FRANCISCO, Nov. 03, 2025 (GLOBE NEWSWIRE) &#8212; Olema Pharmaceuticals, Inc.\u00a0(\u201cOlema\u201d, or \u201cOlema Oncology\u201d, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced that the Company will participate in the following upcoming investor conferences: Guggenheim 2 nd Annual Healthcare Innovation Conference Date and Time: November 10, 2025 at 10:30 a.m. ET Format: Fireside ChatLocation: Boston, MA UBS Global Healthcare Conference 2025 Date and Time: November 12, 2025 at 8:00 a.m. ETFormat: PresentationLocation: Palm Beach, FL 2025 Jefferies London Healthcare Conference Date and Time: November 19, 2025 at 9:00 a.m. GMT \/ 4:00 a.m. ETFormat: Fireside ChatLocation: London Live webcasts and recordings of these presentations will be &hellip; Continue reading \"Olema Oncology to Participate in Upcoming Investor Conferences\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/olema-oncology-to-participate-in-upcoming-investor-conferences-4\/","og_site_name":"Market Newsdesk","article_published_time":"2025-11-04T00:10:36+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU2NzYzMCM3MjQwODM2IzIyMDM1MTU=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/olema-oncology-to-participate-in-upcoming-investor-conferences-4\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/olema-oncology-to-participate-in-upcoming-investor-conferences-4\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Olema Oncology to Participate in Upcoming Investor Conferences","datePublished":"2025-11-04T00:10:36+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/olema-oncology-to-participate-in-upcoming-investor-conferences-4\/"},"wordCount":273,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/olema-oncology-to-participate-in-upcoming-investor-conferences-4\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU2NzYzMCM3MjQwODM2IzIyMDM1MTU=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/olema-oncology-to-participate-in-upcoming-investor-conferences-4\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/olema-oncology-to-participate-in-upcoming-investor-conferences-4\/","name":"Olema Oncology to Participate in Upcoming Investor Conferences - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/olema-oncology-to-participate-in-upcoming-investor-conferences-4\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/olema-oncology-to-participate-in-upcoming-investor-conferences-4\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU2NzYzMCM3MjQwODM2IzIyMDM1MTU=","datePublished":"2025-11-04T00:10:36+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/olema-oncology-to-participate-in-upcoming-investor-conferences-4\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/olema-oncology-to-participate-in-upcoming-investor-conferences-4\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/olema-oncology-to-participate-in-upcoming-investor-conferences-4\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU2NzYzMCM3MjQwODM2IzIyMDM1MTU=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU2NzYzMCM3MjQwODM2IzIyMDM1MTU="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/olema-oncology-to-participate-in-upcoming-investor-conferences-4\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Olema Oncology to Participate in Upcoming Investor Conferences"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/904745","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=904745"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/904745\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=904745"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=904745"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=904745"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}